Loading...

CorMedix Inc.

CRMDNASDAQ
HealthcareBiotechnology
$13.98
$0.80(6.07%)

CorMedix Inc. (CRMD) Stock Overview

Explore CorMedix Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.00%
Profit Growth
$0.26
61.31%
EPS Growth
$0.26
67.03%
Operating Margin
17.53%
54.34%
ROE
22.57%
61.31%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$9.00
Average$9.00
High$9.00

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CEO

Mr. Joseph Todisco MBA

Employees

64

Headquarters

300 Connell Drive, Berkeley Heights, NJ

Founded

2010

Frequently Asked Questions